The anti-CD20 monoclonal antibody rituximab, first approved for clinical use in 1997, has changed the standard of care for many patients with non-Hodgkin's lymphoma (NHL). Recent data from large randomized clinical trials confirm that the addition of rituximab to standard chemotherapy regimens (chemoimmunotherapy) improves both response rates and survival outcomes in patients with follicular NHL and diffuse large B cell lymphoma (DLBCL), the two most common subtypes of NHL. Population-based analyses have found substantial improvements in NHL survival over the past decade; studies indicate that rituximab has favorably altered the long-term prognosis of follicular NHL and DLBCL patients. This review discusses the clinical development of rituximab-based therapies for patients with low-grade or follicular NHL and newly diagnosed DLBCL, highlighting recent key randomized trials with a focus on survival outcomes.

中文翻译：

---

利妥昔单抗的十年：改善非霍奇金淋巴瘤的生存结果。

抗CD20单克隆抗体利妥昔单抗（rituximab）于1997年首次批准用于临床，它改变了许多非霍奇金淋巴瘤（NHL）患者的治疗标准。来自大型随机临床试验的最新数据证实，在标准的化疗方案（化学免疫疗法）中添加利妥昔单抗可改善滤泡性NHL和弥散性大B细胞淋巴瘤（DLBCL）（这是NHL的两种最常见的亚型）患者的缓解率和生存结果。基于人群的分析发现，过去十年来，NHL的生存率有了实质性的提高。研究表明，利妥昔单抗改变了滤泡性NHL和DLBCL患者的长期预后。这篇综述讨论了以利妥昔单抗为基础的治疗对于低度或滤泡性NHL和新诊断为DLBCL的患者的临床进展，